Intec Pharma to delist shares from Tel Aviv bourse
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Intec Pharma Ltd. will voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange.
The delisting will take place in three months, with the shares continuing to trade on the exchange in the interim.
The Jerusalem-based drug developer's shares will remain listed on the Nasdaq Capital Market, and will transfer shares trading in Tel Aviv to the U.S. exchange.
